October 18, 2012, Billerica, MA — EMD Millipore, the Life Science division of Merck KGaA, Darmstadt, Germany, today announced projected 2013 pricing for products associated with Process Solution’s Pharm Chemical Solutions (PCS) and Biopharm Process Solutions (BPS) business fields. Effective January 1st, 2013, prices will increase by an average of 4-6%. The price adjustments are being driven by recent and anticipated cost increases, macroeconomic trends and inflation among other considerations. The price increases will differ by product lines depending on the specific impact of cost drivers and market dynamics.
“The 2013 price increase for Process Solutions products reflects the impact of higher costs, associated with raw materials, energy and labor, and increased regulatory demands on the pharmaceutical and biopharmaceutical industry,” said Andrew Bulpin, Head of Process Solutions at EMD Millipore. “These nominal price modifications will help us continue delivering the high level of quality products, pharmaceutical ingredients and services our customers expect, thereby ensuring patient safety and increasing speed to market.”
EMD Millipore is the Life Science division of Merck KGaA, Darmstadt, Germany, offers a broad range of innovative, performance products, services and business relationships that enable our customers' success in research, development and production of biotech and pharmaceutical drug therapies. Through dedicated collaboration on new scientific and engineering insights, and as one of the top three R&D investors in the Life Science Tools industry, EMD Millipore serves as a strategic partner to customers and helps advance the promise of life science.
Headquartered in Billerica, Massachusetts, the division has around 10,000 employees, operations in 67 countries and 2011 revenues of EUR 2.4 billion.